Elizabeth C Okafor
Overview
Explore the profile of Elizabeth C Okafor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okurut S, Boulware D, Manabe Y, Tugume L, Skipper C, Ssebambulidde K, et al.
PLoS Negl Trop Dis
. 2025 Feb;
19(2):e0012873.
PMID: 39928682
Introduction: Cryptococcal meningitis remains a prominent cause of death in persons with advanced HIV disease. CSF leukocyte infiltration predicts survival at 18 weeks; however, how CSF immune response relates to...
2.
Okafor E, Nielsen K
J Fungi (Basel)
. 2024 Oct;
10(10).
PMID: 39452664
is an environmental pathogen that causes life-threatening disease in immunocompromised persons. The majority of immunological studies have centered on CD4 T-cell dysfunction and associated cytokine signaling pathways, optimization of phagocytic...
3.
Kasibante J, Irfanullah E, Wele A, Okafor E, Ssebambulidde K, Okurut S, et al.
Med Mycol
. 2024 Oct;
62(10).
PMID: 39419774
Cerebrospinal fluid (CSF) protein levels exhibit high variability in HIV-associated cryptococcal meningitis; however, its clinical implications remain unclear. We analyzed data from 890 adults with HIV-associated cryptococcal meningitis randomized into...
4.
Okafor E, Mukaremera L, Hullsiek K, Engen N, Tugume L, Ssebambulidde K, et al.
J Infect Dis
. 2024 Aug;
231(2):521-531.
PMID: 39207255
Background: The role of the immune response in acute mortality of cryptococcal meningitis remains unclear. Methods: Cerebrospinal fluid (CSF) from 337 Ugandans with first-episode cryptococcal meningitis was collected. CSF cytokines...
5.
Lofgren S, Okafor E, Colette A, Pastick K, Skipper C, Pullen M, et al.
Open Forum Infect Dis
. 2022 May;
8(11):ofab506.
PMID: 35548171
Background: During the coronavirus disease 2019 (COVID-19) pandemic, clinical trials necessitated rapid testing to be performed remotely. Dried blood spot (DBS) techniques have enabled remote HIV virologic testing globally, and...
6.
Pullen M, Pastick K, Williams D, Nascene A, Bangdiwala A, Okafor E, et al.
Open Forum Infect Dis
. 2021 Feb;
8(2):ofaa602.
PMID: 33553471
As the severe acute respiratory syndrome coronavirus 2 pandemic evolved, it was apparent that well designed and rapidly conducted randomized clinical trials were urgently needed. However, traditional clinical trial design...
7.
Lofgren S, Nicol M, Bangdiwala A, Pastick K, Okafor E, Skipper C, et al.
Open Forum Infect Dis
. 2020 Nov;
7(11):ofaa500.
PMID: 33204764
Background: Use of hydroxychloroquine in hospitalized patients with coronavirus disease 2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from 3 outpatient randomized...
8.
Okafor E, Hullsiek K, Williams D, Scriven J, Rhein J, Nabeta H, et al.
Mediators Inflamm
. 2020 Nov;
2020:8818044.
PMID: 33177951
Background: Though peripheral blood is a crucial sample to study immunology, it is unclear whether the immune environment in the peripheral vasculature correlates with that at the end-organ site of...
9.
Pullen M, Skipper C, Hullsiek K, Bangdiwala A, Pastick K, Okafor E, et al.
Open Forum Infect Dis
. 2020 Oct;
7(7):ofaa271.
PMID: 33117855
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due to insufficient diagnostic testing in the United States, there...
10.
Rajasingham R, Bangdiwala A, Nicol M, Skipper C, Pastick K, Axelrod M, et al.
Clin Infect Dis
. 2020 Oct;
72(11):e835-e843.
PMID: 33068425
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine...